CN101491608B - Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof - Google Patents
Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof Download PDFInfo
- Publication number
- CN101491608B CN101491608B CN2009100047844A CN200910004784A CN101491608B CN 101491608 B CN101491608 B CN 101491608B CN 2009100047844 A CN2009100047844 A CN 2009100047844A CN 200910004784 A CN200910004784 A CN 200910004784A CN 101491608 B CN101491608 B CN 101491608B
- Authority
- CN
- China
- Prior art keywords
- ethanol
- total organic
- organic acids
- filtrate
- total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000002775 capsule Substances 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title abstract description 10
- 229940079593 drug Drugs 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 120
- 238000010828 elution Methods 0.000 claims abstract description 37
- 239000000706 filtrate Substances 0.000 claims abstract description 32
- 150000007524 organic acids Chemical class 0.000 claims abstract description 32
- 229930182490 saponin Natural products 0.000 claims abstract description 32
- 150000007949 saponins Chemical class 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000011347 resin Substances 0.000 claims abstract description 30
- 229920005989 resin Polymers 0.000 claims abstract description 30
- 239000012153 distilled water Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000003480 eluent Substances 0.000 claims abstract description 14
- 238000003809 water extraction Methods 0.000 claims abstract description 7
- 235000005985 organic acids Nutrition 0.000 claims description 28
- 235000017709 saponins Nutrition 0.000 claims description 28
- 238000009835 boiling Methods 0.000 claims description 24
- 239000002244 precipitate Substances 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- 230000000274 adsorptive effect Effects 0.000 claims description 12
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 210000001367 artery Anatomy 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 210000003462 vein Anatomy 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 abstract description 10
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 238000001914 filtration Methods 0.000 abstract description 5
- 241000159213 Zygophyllaceae Species 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 4
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 abstract 2
- 241001092040 Crataegus Species 0.000 abstract 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 2
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 2
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 2
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 2
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 2
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 2
- 241000735234 Ligustrum Species 0.000 abstract 2
- 241000219061 Rheum Species 0.000 abstract 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 2
- 239000003463 adsorbent Substances 0.000 abstract 2
- 229940107666 astragalus root Drugs 0.000 abstract 2
- 235000009165 saligot Nutrition 0.000 abstract 2
- 238000002481 ethanol extraction Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 14
- 210000003494 hepatocyte Anatomy 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 9
- 210000000582 semen Anatomy 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 241000756943 Codonopsis Species 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical group C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 229960003765 fluvastatin Drugs 0.000 description 3
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 241000007126 Codonopsis pilosula Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 240000004980 Rheum officinale Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 241000357628 Codonopsis pilosula subsp. tangshen Species 0.000 description 1
- 240000008142 Crambe tatarica Species 0.000 description 1
- 241000657480 Crataegus pinnatifida Species 0.000 description 1
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 241000092728 Eleutherococcus gracilistylus Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000205407 Polygonum Species 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 241000731396 Pueraria montana var. thomsonii Species 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 241001533104 Tribulus terrestris Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229960002545 methylthiouracil Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000008492 tangshen Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a medicine for a pulse-invivorating and fat-regulating capsule compound effective part group and a process for preparing the same. The effective part group is total saponin and total organic acid, wherein the total saponin is prepared from astragalus root, hawthorn and caltrop; and the total organic acid is prepared from privet and rhubarb. The process comprises that: the astragalus root, hawthorn and caltrop are mixed, and subjected to water extraction, filtering and alcohol disposition, the water bath concentrated solution of the alcohol disposition filtrate obtained is placed on a macroporous adsorbent resin column and orderly eluted by distilled water and ethanol, the obtained eluent is distilled to dryness to prepare the total saponin; the privet and rhubarb are mixed, and subjected to ethanol extraction and filtering, the filtrate is concentrated in water bath, placed on a macroporous adsorbent resin column and subjected to gradient elution orderly by distilled water and ethanol, the obtained eluent is distilled to dryness to prepare the total organic acid; and the total saponin and the total organic acid are mixed to prepare the effective part group. In the formulation of the medicine, pure natural traditional Chinese medicines are adopted, thereby reducing fat, protecting the liver, causing no toxic and side effects to human body, and having simple preparation process, easy operation and high extraction efficiency.
Description
The applying date of original application: on January 12nd, 2007
Application number: 200710008433.1
Invention and created name: the pharmaceutical formulation and the preparation technology of the arteries and veins blood fat regulating capsule compound effective site group of living
Technical field
The present invention relates to the prescription and the preparation technology of medicine, relate to a kind of medicine and preparation technology thereof of the arteries and veins blood fat regulating capsule compound effective site group of living more specifically.
Background technology
At present, along with the raising of people's living standard, intake higher fatty acid, high heat food also increases day by day.The sickness rate of diseases such as fatty liver, hyperlipidemia, obesity, arteriosclerosis, cerebral thrombosis, coronary heart disease increases year by year, and is rejuvenation trend.Generally adopt Western medicine to carry out blood fat reducing treatment clinically,, take for a long time and can produce a lot of toxic and side effects, as liver, kidney being caused damage etc. human body based on cholesterol reducing or triglyceride.
Summary of the invention
Goal of the invention of the present invention is at the problems referred to above, and a kind of medicine and preparation technology thereof of the arteries and veins blood fat regulating capsule compound effective site group of living is provided, and is intended to reach the purpose that blood fat reducing protects the liver again.
The present invention prepares the pharmaceutical formulation of arteries and veins blood fat regulating capsule compound effective site group alive, and wherein effective part group is total saponins and total organic acids; The percentage by weight of the pharmaceutical formulation component of preparation total saponins is: the Radix Astragali or Radix Codonopsis or Cortex Acanthopancis 30～45%, Radix Salviae Miltiorrhizae or Rhizoma Curcumae Longae or Fructus Crataegi 30～45%, Fructus Tribuli or Radix Puerariae 10～25%; The percentage by weight of the pharmaceutical formulation component of preparation total organic acids is: Fructus Ligustri Lucidi 80～90%, Radix Et Rhizoma Rhei or Semen Cassiae 10～20%.
Step of preparation process of the present invention is:
1) processing step of preparation total saponins is: with the Radix Astragali or Radix Codonopsis or Cortex Acanthopancis, Radix Salviae Miltiorrhizae or Rhizoma Curcumae Longae or Fructus Crataegi, Fructus Tribuli or Radix Puerariae mix by above-mentioned prescription, with with raw material weight than the water extraction 1～3 time that is 8～12 times of amounts, each 0.5～1.5 hour, merge extractive liquid,, filter, filtrate is 50～90% ethanol precipitate with ethanol with concentration, standing over night, filter, reclaim precipitate with ethanol filtrate, precipitate with ethanol filtrate concentrated and be settled to 100 ℃ of boiling water-baths contain the concentrated solution that total saponins concentration is 0.5～2g/ml, with AB-S type macroporous adsorptive resins on the concentrated solution, be the distilled water of 6～10 times of resin volumes and 30～70% ethanol elution with volume successively, elution flow rate 1～3ml/min, collect 30～70% ethanol elution, eluent is made total saponins at 100 ℃ of boiling water bath methods;
2) processing step of preparation total organic acids is: Fructus Ligustri Lucidi, Radix Et Rhizoma Rhei or Semen Cassiae are mixed by above-mentioned prescription, with with raw material weight than 50～95% alcohol reflux 1～3 time that are 6～10 times of amounts, each 1～2h, merge extractive liquid,, filter, reclaim filtrate, filtrate is concentrated and is settled to 100 ℃ of boiling water-bath contain the concentrated solution that total organic acids concentration is 0.5～2g/ml; With AB-S type macroporous adsorptive resins on the concentrated solution, be distilled water, 10～30% ethanol and 70～95% ethanol gradient elutions of 6～10 times of resin volumes successively with volume, elution flow rate is 1～3ml/min, collect 70～95% ethanol elution, eluent is made total organic acids at 100 ℃ of boiling water bath methods;
3) be that 1: 1～10: 1 total saponins and total organic acids is mixed and made into effective part group with weight ratio.
Remarkable advantage of the present invention is: this pharmaceutical formulation all is the natural Chinese medicines material, and not only blood fat reducing but also protect the liver has no side effect to human body, and preparation technology is simple, operation, extraction efficiency height easily.
The specific embodiment
With the Radix Astragali or Radix Codonopsis or Cortex Acanthopancis, Radix Salviae Miltiorrhizae or Rhizoma Curcumae Longae or Fructus Crataegi, Fructus Tribuli or Radix Puerariae mix by above-mentioned prescription, with with raw material weight than the water extraction 1～3 time that is 8～12 times of amounts, each 0.5～1.5 hour, merge extractive liquid,, filter, filtrate is 50～90% ethanol precipitate with ethanol with concentration, standing over night, filter, reclaim precipitate with ethanol filtrate, precipitate with ethanol filtrate concentrated and be settled to 100 ℃ of boiling water-baths contain the concentrated solution that total saponins concentration is 0.5～2g/ml, with AB-S type macroporous adsorptive resins on the concentrated solution, be the distilled water of 6～10 times of resin volumes and 30～70% ethanol elution with volume successively, elution flow rate 1～3ml/min, collect 30～70% ethanol elution, eluent is made total saponins at 100 ℃ of boiling water bath methods.
Fructus Ligustri Lucidi, Radix Et Rhizoma Rhei or Semen Cassiae are mixed by above-mentioned prescription, with with raw material weight than 50～95% alcohol reflux 1～3 time that are 6～10 times of amounts, each 1～2h, merge extractive liquid,, filter, reclaim filtrate, filtrate is concentrated and is settled to 100 ℃ of boiling water-bath contain the concentrated solution that total organic acids concentration is 0.5～2g/ml; With AB-S type macroporous adsorptive resins on the concentrated solution, be distilled water, 10～30% ethanol and 70～95% ethanol gradient elutions of 6～10 times of resin volumes successively with volume, elution flow rate is 1～3ml/min, collect 70～95% ethanol elution, eluent is made total organic acids at 100 ℃ of boiling water bath methods.
With weight ratio is that 1: 1～10: 1 total saponins and total organic acids is mixed and made into effective part group.
Wherein, used medical material Fructus Ligustri Lucidi is mature fruit or the dry blade of Fructus Ligustri Lucidi Ligustrum lucidum.Ait.; The Radix Astragali be adopt leguminous plant Radix Astagali Astragalus membranaceus (Fisch.) Bge, Var mongholicus (Bge) Hsio or Radix Astragali Astragalus membranaceus (Fisch) Bge, dry root; Radix Codonopsis is the root that adopts campanulaceae plant Radix Codonopsis Codonopsis pilosula (Franch.) Nannf., plain flower Radix Codonopsis C.Pilosula Nannf.Var.modesta (Nannf.) L.T.Shen or radix codonpsis tangshen C.tangshen Oliv.; Cortex Acanthopancis is the dry root bark that adopts Araliaceae acanthopanax gracilistylus Acanthopanax gracilistylusW.W.Smith; Radix Salviae Miltiorrhizae is exsiccant and the rhizome that adopts labiate Radix Salviae Miltiorrhizae Salvia miltiorrhiza Bge.; Rhizoma Curcumae Longae is to adopt zingiberaceous plant Rhizoma Curcumae Longae Curcuma longa.L. rhizome; Fructus Crataegi is the mature fruit that adopts rosaceous plant Fructus Pyri Pashiae Crataegus pinnatifida Bge.var.major N.E.Br. or Fructus Crataegi C.pinnatifida Bge.; Fructus Tribuli is the fruit that adopts zygophyllaceae plant Fructus Tribuli Tribulus terrestris L.; Radix Puerariae is the dry root that adopts legume pueraria lobata Pueraria lobata (Willd.) Ohwi or Radix Puerariae rattan Puerariathomsonii Benth.; Radix Et Rhizoma Rhei is the dry root and rhizome that adopts polygonum rheum palmatum Rheum palmatum L., Rheum tanguticum R.tanguticum Maxim.ex Balf. or Rheum officinale R.officinale Baill.; Semen Cassiae is the dry mature seed that adopts leguminous plant Semen Cassiae Cassia obtusifolia L. or little Semen Cassiae C.tora L..
The consumption of resin is 3: 10 with the weight ratio of preparation total saponins raw material consumption in the processing step of preparation total saponins, and the consumption of resin is 3: 5 with the weight ratio of preparation total organic acids raw material consumption in the processing step of preparation total organic acids.
Embodiment 1
With the Radix Astragali, Radix Salviae Miltiorrhizae, Fructus Tribuli mixes by above-mentioned prescription, with with raw material weight than the water extraction 2 times that is 8 times of amounts, each 1 hour, merge extractive liquid,, filter, filtrate is 70% ethanol precipitate with ethanol with concentration, standing over night is filtered, and reclaims precipitate with ethanol filtrate, precipitate with ethanol filtrate concentrated and be settled to 100 ℃ of boiling water-baths contain the concentrated solution that total saponins concentration is 1g/ml, with AB-S type macroporous adsorptive resins on the concentrated solution, be the distilled water of 8 times of resin volumes and 60% ethanol elution with volume successively, elution flow rate 1.5ml/min, collect 60% ethanol elution, eluent is made total saponins at 100 ℃ of boiling water bath methods.
Fructus Ligustri Lucidi, Radix Et Rhizoma Rhei are mixed by above-mentioned prescription, use with raw material weight than 80% alcohol reflux 2 times that is 8 times of amounts, 1h at every turn, merge extractive liquid,, filtrate is reclaimed in filtration, filtrate is concentrated and is settled to 100 ℃ of boiling water-bath contain the concentrated solution that total organic acids concentration is 1g/ml; With AB-S type macroporous adsorptive resins on the concentrated solution, be distilled water, 10% ethanol and 70% ethanol gradient elution of 10 times of resin volumes successively with volume, elution flow rate is 1.5ml/min, collects 70% ethanol elution, and eluent makes total organic acids at 100 ℃ of boiling water bath methods.
With weight ratio is that 1: 1 total saponins and total organic acids is mixed and made into effective part group.
Embodiment 2
With Radix Codonopsis, Radix Salviae Miltiorrhizae, Fructus Tribuli mixes by above-mentioned prescription, with with raw material weight than the water extraction 2 times that is 10 times of amounts, each 1 hour, merge extractive liquid,, filter, filtrate is 80% ethanol precipitate with ethanol with concentration, standing over night is filtered, and reclaims precipitate with ethanol filtrate, precipitate with ethanol filtrate concentrated and be settled to 100 ℃ of boiling water-baths contain the concentrated solution that total saponins concentration is 1g/ml, with AB-S type macroporous adsorptive resins on the concentrated solution, be the distilled water of 8 times of resin volumes and 60% ethanol elution with volume successively, elution flow rate 1.5ml/min, collect 60% ethanol elution, eluent is made total saponins at 100 ℃ of boiling water bath methods.
Fructus Ligustri Lucidi, Radix Et Rhizoma Rhei are mixed by above-mentioned prescription, use with raw material weight than 80% alcohol reflux 2 times that is 8 times of amounts, 1h at every turn, merge extractive liquid,, filtrate is reclaimed in filtration, filtrate is concentrated and is settled to 100 ℃ of boiling water-bath contain the concentrated solution that total organic acids concentration is 1g/ml; With AB-S type macroporous adsorptive resins on the concentrated solution, be distilled water, 10% ethanol and 70% ethanol gradient elution of 10 times of resin volumes successively with volume, elution flow rate is 1.5ml/min, collects 70% ethanol elution, and eluent is made total organic acids at 100 ℃ of boiling water bath methods.
With weight ratio is that 1: 1 total saponins and total organic acids is mixed and made into effective part group.
Embodiment 3
With the Radix Astragali, Fructus Crataegi, Fructus Tribuli mixes by above-mentioned prescription, with with raw material weight than the water extraction 3 times that is 8 times of amounts, each 1 hour, merge extractive liquid,, filter, filtrate is 75% ethanol precipitate with ethanol with concentration, standing over night is filtered, and reclaims precipitate with ethanol filtrate, precipitate with ethanol filtrate concentrated and be settled to 100 ℃ of boiling water-baths contain the concentrated solution that total saponins concentration is 1g/ml, with AB-S type macroporous adsorptive resins on the concentrated solution, be the distilled water of 8 times of resin volumes and 60% ethanol elution with volume successively, elution flow rate 1.5ml/min, collect 60% ethanol elution, eluent is made total saponins at 100 ℃ of boiling water bath methods.
Fructus Ligustri Lucidi, Radix Et Rhizoma Rhei are mixed by above-mentioned prescription, use with raw material weight than 80% alcohol reflux 2 times that is 8 times of amounts, 1h at every turn, merge extractive liquid,, filtrate is reclaimed in filtration, filtrate is concentrated and is settled to 100 ℃ of boiling water-bath contain the concentrated solution that total organic acids concentration is 1g/ml; With AB-S type macroporous adsorptive resins on the concentrated solution, be distilled water, 10% ethanol and 70% ethanol gradient elution of 10 times of resin volumes successively with volume, elution flow rate is 1.5ml/min, collects 70% ethanol elution, and eluent is made total organic acids at 100 ℃ of boiling water bath methods.
With weight ratio is that 1: 1 total saponins and total organic acids is mixed and made into effective part group.
The pharmacological research test of effective part group
(1) effective part group is to the influence of rat fat
The rat adaptability fed for 1 week, was divided into normal blank group and modeling group at random.Normal rats is irritated the stomach normal saline; Modeling group rat is adopted and irritates the modeling of stomach lipomul method, and lipomul is formed: 10g cholesterol, 20g Adeps Sus domestica, 2g sodium cholate, 1g methylthiouracil, 20ml tween 80,20ml propylene glycol add water and be mixed into 100ml in right amount.Feed after 7 days, eye socket is got blood, surveys serum TC, TG.
According to the body weight of modeling group rat and TC, TG level, be divided into 6 groups at random.Blank group, model group, fluvastatin group (3.6mgkg
-1), former side organizes (1400mgkg
-1), effective part group high dose group (375mgkg
-1), dosage group (188mgkg in the effective part group
-1), effective part group low dose group (62.5mgkg
-1), 10 every group.
Rat is given different sample medicinal liquids by different groups, twice of normal control group every filling stomach distilled water every day (1ml/100g); Model group every filling stomach lipomul every day and distilled water are respectively once; Administration group every filling stomach lipomul every day and different pharmaceutical are respectively once.Feed continuously and administration 30d.And claim its body weight respectively at 0d, 7d, 14d, 21d, 28d.Fasting 12 hours (can't help water) after the last administration, the back broken end of weighing is got blood, and separation of serum is measured the every index of blood fat respectively.T-CHOL (TC) is measured with direct method with direct method mensuration, low-density lipoprotein cholesterol (LDL-C) with oxidation enzymatic assays, HDL-C (HDL-C) with oxidation enzymatic assays, triglyceride (TG), the results are shown in Table 1.
The effect of table 1 effective part group treatment experimental rat hyperlipemia
Annotate: the t check, each administration group and model group be △ P＜0.05 relatively, △ △ P＜0.01; With former side's group comparison ▲ P＜0.05; Compare * P＜0.05, * * P＜0.01 with the blank group.
Table 1 result shows: model group Serum TC, LDL content are apparently higher than blank group (P＜0.01).Each dosage group of effective part group and fluvastatin group can make Serum TC, TG, LDL-C content obviously reduce (P＜0.05～0.01), high dose group Serum TC, LDL content relatively have significant difference (P＜0.05) with model group, action intensity and fluvastatin are suitable, and organize more also there was no significant difference (P＞0.05) with former side.The prompting extract part is the active site of full presciption medicine effect effect, imitates no significant difference with full presciption medicine.
(2) effective part group is to the influence of rat acute hepatic injury:
Get 30 rat male and female half and half, be divided into 3 groups at random, 10 every group.Blank group, model group are irritated stomach normal saline 10ml/kg/d, and stomach effective part group 375mg/kg/d irritates in effective site group.Each organizes continuous gastric infusion 7 days, and 1h is except that the blank group is irritated stomach Oleum Arachidis hypogaeae semen (5ml/kg) after the last time administration, and all the other each groups are all irritated stomach 25%CCl
4Peanut oil solution 5ml/kg, overnight fasting, broken end is got blood and is put to death animal behind the 16h, collects blood, and separation of serum is measured alanine aminotransferase (ALT), triglyceride (TG).The results are shown in Table 2.
Cut open the belly immediately after rat is put to death, take out liver and be dipped in 10% the neutral formalin solution, fix 3～4 days, the routine paraffin wax section, HE dyeing, the om observation hepatic tissue pathology changes.The hepar damnification grading is decided to be: hepatocyte edema quantity percentage ratio: 10～20%, 20～30%, 30～40% and 〉=50%; Hepatocyte diffusivity fat range degree: hepatocyte does not have the change of diffusivity fat, the interior rarely seen tiny fat of hepatocyte drips; Hepatocyte special mess degree of necrosis: hepatocyte does not have little focal necrosis; Accidental several necrocytosis kitchen ranges in the lobules of liver.The results are shown in Table 3.
Table 2 effective part group is to the influence of rat blood serum ALT, TG
Annotate: the t check, compare * P＜0.01 with the blank group; Compare △ P＜0.05, △ △ P＜0.01 with model group.
Table 2 result shows: model group rat blood serum ALT level significantly raises (P＜0.01) than the blank group, and CCl is described
4Cause acute liver damage modelling success.The rat blood serum ALT of effective site group level significantly reduces (P＜0.05) than model group, and the serum TG level obviously raises than model group, but not statistically significant (P＞0.05).
Table 3 effective part group is to the histological influence of experimental rat hepatic pathology
Histopathology result shows: (one) perusal: blank group finding liver is chocolate, its smooth surface, and matter is medium; The increase of model group liver is the dull gray redness, and very the person is grey yellowish red color, or sees the yellowish-brown fleck, and peplos is nervous, smooth, and matter is softer; Effective site group liver slightly increases, and the surface is chocolate or little Huang, or accidental yellowish-brown fleck, and peplos is nervous, and matter is soft slightly.(2) light microscopy checking: see liver rope queueing discipline under the blank group liver tissues of rats structure mirror, the hepatocyte form is normal, nucleus circle or oval, and placed in the middle, sinus hepaticus and portal area are no abnormal; The banded edema of the hepatocyte that visible level does not wait under the model arrangement of mirrors, cell rope arrangement disorder, and slight fat change of popularity and accidental little focal necrosis, most of banded edema expands for central authorities and to the portal area and prolongs; And effective site group hepatocyte edema quantity, fat change and little focal necrosis all obviously alleviate than model group, alleviate obviously with hepatocyte edema quantity especially, and most hepatocyte have confirmed that near the blank group effective part group is to CCL
4Cause hepatic injury and have protective effect.
Claims (3)
1. arteries and veins blood fat regulating capsule alive, it is characterized in that: described capsular effective part group is total saponins and total organic acids; The percentage by weight of the pharmaceutical formulation component of described preparation total saponins is: the Radix Astragali 30～45%, Fructus Crataegi 30～45%, Fructus Tribuli 10～25%; The percentage by weight of the pharmaceutical formulation component of described preparation total organic acids is: Fructus Ligustri Lucidi 80～90%, Radix Et Rhizoma Rhei 10～20%;
Step of preparation process is:
1) processing step of preparation total saponins is: with the Radix Astragali, Fructus Crataegi, Fructus Tribuli mixes by above-mentioned prescription, with with raw material weight than the water extraction 1～3 time that is 8～12 times of amounts, each 0.5～1.5 hour, merge extractive liquid,, filter, filtrate is 50～90% ethanol precipitate with ethanol with concentration, standing over night, filter, reclaim precipitate with ethanol filtrate, precipitate with ethanol filtrate concentrated and be settled to 100 ℃ of boiling water-baths contain the concentrated solution that total saponins concentration is 0.5～2g/ml, with AB-S type macroporous adsorptive resins on the concentrated solution, be the distilled water of 6～10 times of resin volumes and 30～70% ethanol elution with volume successively, elution flow rate 1～3ml/min, collect 30～70% ethanol elution, eluent is made total saponins at 100 ℃ of boiling water bath methods;
2) processing step of preparation total organic acids is: Fructus Ligustri Lucidi, Radix Et Rhizoma Rhei are mixed by above-mentioned prescription, with with raw material weight than 50～95% alcohol reflux 1～3 time that are 6～10 times of amounts, each 1～2h, merge extractive liquid,, filter, reclaim filtrate, filtrate is concentrated and is settled to 100 ℃ of boiling water-bath contain the concentrated solution that total organic acids concentration is 0.5～2g/ml; With AB-S type macroporous adsorptive resins on the concentrated solution, be distilled water, 10～30% ethanol and 70～95% ethanol gradient elutions of 6～10 times of resin volumes successively with volume, elution flow rate is 1～3ml/min, collect 70～95% ethanol elution, eluent is made total organic acids at 100 ℃ of boiling water bath methods;
3) be that 1: 1～10: 1 total saponins and total organic acids is mixed and made into effective part group with weight ratio.
2. arteries and veins blood fat regulating capsule alive according to claim 1 is characterized in that: described Fructus Ligustri Lucidi is mature fruit or the dry blade of Fructus Ligustri Lucidi.
3. arteries and veins blood fat regulating capsule alive according to claim 1, it is characterized in that: the consumption of resin is 3: 10 with the weight ratio of preparation total saponins raw material consumption in the processing step of described preparation total saponins, and the consumption of resin is 3: 5 with the weight ratio of preparation total organic acids raw material consumption in the processing step of described preparation total organic acids.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100047844A CN101491608B (en) | 2007-01-12 | 2007-01-12 | Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100047844A CN101491608B (en) | 2007-01-12 | 2007-01-12 | Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710008433A Division CN100998844B (en) | 2007-01-12 | 2007-01-12 | Medicinal formula of compound effective site group of huomai-tiaozhi capsule and its preparation technology |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101491608A CN101491608A (en) | 2009-07-29 |
| CN101491608B true CN101491608B (en) | 2011-05-04 |
Family
ID=40922508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100047844A Expired - Fee Related CN101491608B (en) | 2007-01-12 | 2007-01-12 | Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101491608B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593571A (en) * | 2004-06-30 | 2005-03-16 | 曹琼 | Chinese traditional medicine for treating hypertension |
-
2007
- 2007-01-12 CN CN2009100047844A patent/CN101491608B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593571A (en) * | 2004-06-30 | 2005-03-16 | 曹琼 | Chinese traditional medicine for treating hypertension |
Non-Patent Citations (1)
| Title |
|---|
| 黄永艳等.中医药治疗高脂血症实验研究进展.《中医药导报》.2006,第12卷(第1期),78,79. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101491608A (en) | 2009-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102233119B (en) | Traditional Chinese medicine composition for treating fatty liver and preparation method thereof | |
| CN101837065B (en) | Medicine with anti-hepatitis, anti-tumour and organism immunity improving functions and preparation method thereof | |
| CN101491595B (en) | Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof | |
| CN102100874A (en) | Chinese patent drug for treating diabetes and preparation method thereof | |
| CN102178867A (en) | Chinese medicine preparation for replenishing qi to invigorate spleen and tonifying kidney and products thereof | |
| CN101810793A (en) | Application of corn stigma flavone in preparing medicament for curing hyperlipidemia and losing weight | |
| WO2016074333A1 (en) | Drug or health care product preventing or treating liver and kidney damage-related diseases and use thereof | |
| CN1403146A (en) | Medicines composition for treating diabetes and its prepn | |
| CN103860699A (en) | Pharmaceutical composition for radically treating hypertension, hyperlipidemia and hyperglycemia | |
| CN100998844B (en) | Medicinal formula of compound effective site group of huomai-tiaozhi capsule and its preparation technology | |
| CN103933411B (en) | A kind of Chinese medicine composition treating fatty liver and its production and use | |
| CN1939435B (en) | Hypolipidemic composition and its use | |
| CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
| CN100518809C (en) | Medicinal composition for curing diabetes and nephropathy and its preparing method | |
| CN101342249B (en) | Chinese medicine formulations for treating hepatitis B and preparation method thereof | |
| CN101491608B (en) | Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof | |
| CN109694393A (en) | A kind of extracting method and its application of stachyose | |
| CN109224038A (en) | A kind of Chinese medicine composition of the evodia rutaecarpa containing guiding drug and its preparation method and application for treating obstruction of collaterals by blood stasis type liver fibrosis | |
| CN101632829B (en) | Anti-hepatofibrosis traditional Chinese medicament composition, preparation method thereof and medicament preparation | |
| CN105477213A (en) | Traditional Chinese medicine composition for reducing blood fat and preparation method thereof | |
| CN101322767A (en) | Combination specific to valid target for treating diabetic and use thereof | |
| CN104173681B (en) | Traditional Chinese herbal medicine composition for treating castration-resistant prostate cancer | |
| CN102652791A (en) | Medicinal composition with hepatic fibrosis resistance and preparation method | |
| CN101062207B (en) | Chinese traditional medicine for treating hyperlipomia and the preparation thereof | |
| CN108186909A (en) | The Chinese medicine composition and its compound preparation of improvement insulin resistance syndrome and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110504 Termination date: 20150112 |
|
| EXPY | Termination of patent right or utility model |